Get the Stockscreener App
26.15
24.23%
5.10
After Hours:
26.60
0.45
+1.72%
Arrowhead Pharmaceuticals Inc stock is traded at $26.15, with a volume of 6.65M.
It is up +24.23% in the last 24 hours and up +30.10% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$21.05
Open:
$22.37
24h Volume:
6.65M
Relative Volume:
5.43
Market Cap:
$2.97B
Revenue:
$181.74M
Net Income/Loss:
$-296.81M
P/E Ratio:
-15.29
EPS:
-1.71
Net Cash Flow:
$-402.70M
1W Performance:
+39.76%
1M Performance:
+30.10%
6M Performance:
+5.10%
1Y Performance:
-8.92%
1-Day Range:
$22.25
$26.62
1-Week Range:
$18.13
$26.62
52-Week Range:
$17.05
$39.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
26.15 | 2.97B | 181.74M | -296.81M | -402.70M | -1.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSN
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk (NASDAQ:ARWR) - Seeking Alpha
Insiders Sold US$1.6m Of Arrowhead Pharmaceuticals Stock Possibly Sending Warning Sign - Simply Wall St
Arrowhead Stock Rockets 16% After Major Licensing Deal - GuruFocus.com
Earnings call: Arrowhead Pharmaceuticals reports transformative year By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Buy Rating from Chardan Capital - MarketBeat
Arrowhead and Sarepta link for rare genetic disease treatments - Pharmaceutical Technology
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Yahoo Finance
Arrowhead Pharmaceuticals Eyes Future Growth with Strategic Deals - TipRanks
Arrowhead climbs after licensing deal with Sarepta - MSN
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - BioSpace
Earnings call: Arrowhead Pharmaceuticals reports transformative year - Investing.com
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal - Yahoo! Voices
Arrowhead, Sarepta Launch On A Whopping $11.38 Billion Deal - Investor's Business Daily
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartzy
Arrowhead Pharmaceuticals Reports Q4 EPS of -$5.00, Missing Esti - GuruFocus.com
Arrowhead Pharmaceuticals Fiscal Q4 Loss Widens, Revenue Declines - Marketscreener.com
Arrowhead Pharma, Sarepta TX ink new gene therapy deal - Yahoo Finance
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? - Benzinga
More than $11 billion at stake in Arrowhead and Sarepta deal - The Pharma Letter
J.M. Smucker Posts Upbeat Earnings, Joins… - Inkl
Arrowhead stock soars on $825M Sarepta Therapeutics deal - Investing.com
Arrowhead stock soars on $825M Sarepta Therapeutics deal By Investing.com - Investing.com UK
Arrowhead stock up on Sarepta licensing deal (ARWR:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - BioSpace
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal - MarketWatch
Sarepta Therapeutics (SRPT) Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals (ARWR) for Multiple Clinical and Preclinical siRNA Programs - StreetInsider.com
Sarepta Lands Major $825M Deal with Arrowhead for 7 Drug Programs & siRNA Platform | ARWR Stock News - StockTitan
Arrowhead Pharmaceuticals Submits FDA Application for Plozasiran in Familial Chylomicronemia Syndrome - Pharmacy Times
Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $45.33 Average PT from Analysts - MarketBeat
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
(ARWR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock faces pivotal moment - Investing.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Cut by Principal Financial Group Inc. - MarketBeat
Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart
Familial Hypercholesterolemia Market Forecasted to Surge - openPR
Familial Chylomicronemia Syndrome Market Expected - openPR
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday - MarketBeat
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace
Arrowhead seeks FDA nod for rare disease drug - Investing.com
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace
An RNAi renaissance is creating a new generation of startups - Yahoo Finance
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace
The Practice-Changing Drugs That Will Graduate In 2025 - Citeline
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vakiener Victoria | Director |
May 02 '24 |
Sale |
23.31 |
1,799 |
41,935 |
30,205 |
| Hamilton James C | Chief Discovery/Trans Medicine |
Apr 01 '24 |
Sale |
28.03 |
6,000 |
168,180 |
204,851 |
| Lu Hongbo | Director |
Mar 19 '24 |
Buy |
28.00 |
1,000 |
28,000 |
32,680 |
| Lu Hongbo | Director |
Mar 20 '24 |
Buy |
27.50 |
1,000 |
27,500 |
33,680 |
| Lu Hongbo | Director |
Mar 18 '24 |
Buy |
27.49 |
1,000 |
27,490 |
31,680 |
| Myszkowski Kenneth Allen | Chief Financial Officer |
Mar 06 '24 |
Sale |
35.19 |
40,000 |
1,407,600 |
400,600 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Option Exercise |
14.54 |
57,499 |
836,035 |
3,772,547 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Sale |
32.35 |
57,499 |
1,860,019 |
3,715,048 |
| Hamilton James C | Chief Discovery/Trans Medicine |
Jan 12 '24 |
Sale |
36.89 |
7,940 |
292,904 |
210,851 |
| GIVEN DOUGLAS B | Director |
Jan 11 '24 |
Sale |
38.06 |
2,911 |
110,788 |
129,711 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):